豪森藥業(yè)
  • Overview
  • 1995 Initial establishment
    A principal subsidiary of Hansoh Pharma (03692.HK)
    7
    Launched innovative drugs
    Top 100
    Pharmaceutical companies worldwide
    Top 3
    China's best Industrial enterprises in pharmaceutical R&D pipeline

Therapy Areas

  • Anti-tumor
    Anti-tumor
    Anti-tumor
    Anti-tumor
    Anti-tumor
    Anti-tumor
    We focus on the develoment of new drugs in the field of common and hostile cancers.Our innovative medicine programs in clinical trials include HS-20106 injection, HS-20105 injection, HS-20117 injection, HS-10516 capsules, HS-10382 tablets, HS-10370 tablets, HS-10502 tablets, HS-10365 capsules, HS-20089 injection, HS-20093 injection, HS-10352 tablets, HS-10241 tablets, etc.
    More +
  • Anti-infectives
    Anti-infectives
    Anti-infectives
    Anti-infectives
    Anti-infectives
    Anti-infectives
    We focus on the development of new drugs in the fields of antiviral, anti-complex bacterial infection and anti-fungal infection. Our innovative medicine programs in clinical trials includeCitric Acid Erythorbate tablets, etc.
    More +
  • CNS Diseases
    CNS Diseases
    CNS Diseases
    CNS Diseases
    CNS Diseases
    CNS Diseases
    We focus on the development of new drugs in the fields of psychiatric and neurological disorders.Our innovative medicine programs in clinical trials include HS-10380 tablets, HS-10506 tablets, HS-10353 capsules, HS-10509 tablets, etc.
    More +
  • Metabolic Diseases
    Metabolic Diseases
    Metabolic Diseases
    Metabolic Diseases
    Metabolic Diseases
    Metabolic Diseases
    We focus on the development of new drugs in the field of metabolic diseases such as diabetes and obesity. Our innovative medicine programs in clinical trials include HS-10511 tablets, HS-20094 injection, HS-10384 tablets, HS-10518 capsules, HS-10390 tablets, HS-10501 tablets, and HS-10398 capsules, etc.
    More +
  • Autoimmune Diseases
    Autoimmune Diseases
    Autoimmune Diseases
    Autoimmune Diseases
    Autoimmune Diseases
    Autoimmune Diseases
    We focus on the development of new drugs in the field of autoimmune diseases. Our innovative medicine programs in clinical trials includeHS-10374 tablets etc.
    More +
R&D
Innovation
Jiangsu Hansoh Pharma Research Institute
Jiangsu Hansoh Pharma Research Institute
More
Jiangsu Hansoh Pharma Administrative R&D Center
Jiangsu Hansoh Pharma Administrative R&D Center
More
  • Substantial investment on R&D
    In the first half of 2024, R&D investments increased by 28.7% year-on-year, accounting for 18.4% of the revenue
  • Competitive R&D pipeline
    Over 50 clinical studies for 30 innovative drugs at different clinical development stages.
  • Highly efficient capability to discover innovative drugs
    The R&D pipeline covers peptides , small molecules, biologics, ADC drugs, siRNAs, and more.
A broader world, let's discover together
Join Hansoh Pharma +
Work with us
We welcome talents worldwide to join us with their entrepreneurship and achieve new levels of success in their career!
Join Hansoh Pharma +